Kalvista Pharma CEO Palleiko sells $156k in shares to cover tax obligations
#KalVista Pharmaceuticals #CEO Palleiko #Stock Sale #EKTERLY #HAE Treatment #Analyst Ratings #Tax Obligations
📌 Key Takeaways
- KalVista CEO sold $156k in company shares to cover tax obligations
- The company's HAE treatment EKTERLY exceeded Q4 revenue expectations
- Analysts have positive outlooks with price targets ranging from $29 to $39
- KalVista stock has delivered 46% return over the past year
📖 Full Retelling
KalVista Pharmaceuticals CEO Benjamin L. Palleiko sold 10,034 shares of common stock on February 23, 2026, to cover tax withholding obligations, realizing approximately $156,197 at a weighted average price of $15.5668. The shares were sold within a price range of $15.5253 to $15.566982 per share, as disclosed in regulatory filings. This transaction comes as KalVista shares have delivered a strong 46% return over the past year, with the stock currently trading at $15.77. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value, placing it among opportunities on the Most Undervalued list. Prior to this sale, on February 21, 2026, Palleiko exercised options on 23,250 shares of common stock, which were acquired through the conversion of Restricted Stock Units. The company's recent performance has been bolstered by significant fourth-quarter 2025 revenue of approximately $35 million for its HAE treatment, EKTERLY, surpassing analyst expectations of around $20 million. This strong performance contributed to a full-year revenue of approximately $49 million, following the medication's launch in July 2025. The International Guideline on the Diagnosis and Management of Pediatric Patients with Hereditary Angioedema has recommended EKTERLY as a first-line therapy for acute HAE attacks in adolescents aged 12 and older, further validating its clinical efficacy and safety profile.
🏷️ Themes
Corporate Leadership, Pharmaceutical Performance, Market Analysis
Entity Intersection Graph
No entity connections available yet for this article.
Original Source
try{ var _=i o; . if(!_||_&&typeof _==="object"&&_.expiry Bitcoin slips, wipes out 50% from October record high at session low AMD stock surges 14% on Meta AI partnership deal Wall Street ends higher on tech rebound ahead of State of the Union address Software stocks rebound as Anthropic partnerships ease AI disruption fears (South Africa Philippines Nigeria) Kalvista Pharma CEO Palleiko sells $156k in shares to cover tax obligations By Investing.com Insider Trading Published 02/24/2026, 07:49 PM Kalvista Pharma CEO Palleiko sells $156k in shares to cover tax obligations 0 KALV 1.35% KalVista Pharmaceuticals NASDAQ:KALV Chief Executive Officer Benjamin L. Palleiko sold 10,034 shares of common stock on February 23, 2026, to cover tax withholding obligations. The shares were sold at a weighted average price of $15.5668, realizing approximately $156,197. Prices ranged from $15.5253 to $15.566982 per share.The transaction comes as KalVista shares have delivered a strong 46% return over the past year, currently trading at $15.77. According to InvestingPro analysis, the stock appears undervalued relative to its Fair Value, placing it among opportunities on the Most Undervalued list. On February 21, 2026, Palleiko also exercised options on 23,250 shares of common stock. These shares were acquired through the conversion of Restricted Stock Units, with each unit representing a right to receive one share of KalVista Pharmaceuticals stock for no consideration. In other recent news, KalVista Pharmaceuticals reported significant fourth-quarter 2025 revenue of approximately $35 million for its HAE treatment, EKTERLY, surpassing analyst expectations of around $20 million. This strong performance contributed to a full-year revenue of approximately $49 million, following the medication’s launch in July 2025. The International Guideline on the Diagnosis and Management of Pediatric Patients with Hereditary Angioedema has recommended EKTERLY as a first-line therapy for acute HAE attack...
Read full article at source